Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

Objective To analyze the clinical features of pancreatic cancer patients with liver metastasis and multimodality treatments, and to explore the impact of multimodality treatments on the prognosis of pancreatic cancer patients. Methods We retrospectively analyzed 64 pancreatic cancer patients with liver metastasis hospitalized in The First Affiliated Hospital of Chongqing Medical University from January 2009 to January 2012. Prognostic factors in clinical features and multimodality treatments were analyzed by Kaplan-Meier method and Cox regression model with SPSS19.0 software. Results The median survival time (MST) was 4 month. 6-month, 1-year and 2-year overall survival (OS) were 39.1%, 21.9% and 7.8% respectively. Univariate analysis revealed that there were significant differences in age, pain, anorexia, CA19-9, ALT and GGT levels, surgery, chemotherapy embolism/ transarterial chemotherapy, active treatment and multi-disciplinary treatment. Multivariate analysis showed that extrahepatic metastasis, pain, CA19-9, active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment were closely related to the survival and prognosis of patients. Conclusion In pancreatic cancer patients with liver metastases, pain, CA19-9≥1 000 u/ml and extrahepatic metastases at diagnosis are adverse prognostic factors. Active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment could improve the quality of life and prolong the survival time of pancreatic cancer patients with liver metastases.